Intellia Therapeutics Inc buy JPMorgan Chase & Co.
Start price
12.08.24
/
50%
€19.93
Target price
12.08.25
€50.28
Performance (%)
-53.83%
End price
13.08.25
€9.20
Summary
This prediction ended on 13.08.25 with a price of €9.20. Massive losses of -53.83% were the result for the BUY prediction by JPMorgan_Chase___Co_. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | -4.970% | -4.970% | -15.436% |
| iShares Core DAX® | 1.717% | 3.368% | 5.887% |
| iShares Nasdaq 100 | -4.565% | -4.238% | 21.386% |
| iShares Nikkei 225® | -7.120% | -11.869% | 42.357% |
| iShares S&P 500 | -0.894% | 1.687% | 19.495% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at JPMorgan Chase & Co. from $61.00 to $55.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von JPMorgan_Chase___Co_ gewählte maximale Laufzeit wurde überschritten
Stopped prediction by JPMorgan_Chase___Co_ for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€33.87
31.03.23
31.03.23
€72.55
31.03.24
31.03.24
-24.45%
01.04.24
01.04.24
